Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Quarterly report · Q1

4886.TEDINET S100RJLW
Period2023-04-01 → 2023-06-30
Filed2023-08-07
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥16.0bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥60.5bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥15.3bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥1.7bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥1.7bn2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥1.8bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥5.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.8bn2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥1.9bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥1.8bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥1.4bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.3bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥1.4bn2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥1.3bn2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥89.2bnat 2023-06-30Cons.Assets
Total assets¥87.1bnat 2023-03-31Cons.Assets
Total assets¥84.8bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥32.3bnat 2023-06-30Cons.Liabilities
Total liabilities¥32.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥56.9bnat 2023-06-30Cons.Net assets
Net assets / equity¥54.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥50.5bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥15.2bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥14.5bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥50.512023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥150.082022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥46.942022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio63.8%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio59.6%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-06-30¥55m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-06-30¥42m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-06-30¥13m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-06-30−¥27m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥13m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥13m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥288m
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentsegment profit2023-04-01 → 2023-06-30−¥1m
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥14.4bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥14.4bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥2.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥16.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥16.0bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥13m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥44m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥29m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥15m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30−¥18m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥15m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥15m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥169m
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥124m
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥13.6bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥13.6bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥15m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥1.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 323
ItemContextValueUnit
Net defined benefit liabilityPrior1YearInstant5433000000JPY
Net defined benefit liabilityCurrentQuarterInstant5511000000JPY
Other nclPrior1YearInstant335000000JPY
Other nclCurrentQuarterInstant336000000JPY
Noncurrent liabilitiesPrior1YearInstant14954000000JPY
Noncurrent liabilitiesCurrentQuarterInstant13612000000JPY
LiabilitiesPrior1YearInstant32604000000JPY
LiabilitiesCurrentQuarterInstant32285000000JPY
Capital stockPrior1YearInstant1197000000JPY
Capital stockCurrentQuarterInstant1197000000JPY
Capital surplusPrior1YearInstant1847000000JPY
Capital surplusCurrentQuarterInstant1847000000JPY
Retained earningsPrior1YearInstant49619000000JPY
Retained earningsCurrentQuarterInstant50821000000JPY
Treasury stockPrior1YearInstant-3350000000JPY
Treasury stockCurrentQuarterInstant-3340000000JPY
Shareholders equityPrior1YearInstant49315000000JPY
Shareholders equityCurrentQuarterInstant50527000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant4590000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant5668000000JPY
Foreign currency translation adjustmentPrior1YearInstant405000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant471000000JPY
Remeasurements of defined benefit plansPrior1YearInstant222000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant214000000JPY
Valuation and translation adjustmentsPrior1YearInstant5218000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant6353000000JPY
Net assetsPrior1YearInstant54533000000JPY
Net assetsCurrentQuarterInstant56881000000JPY
Liabilities and net assetsPrior1YearInstant87138000000JPY
Liabilities and net assetsCurrentQuarterInstant89166000000JPY
Net salesPrior1YTDDuration15269000000JPY
Net salesCurrentYTDDuration16023000000JPY
Cost of salesPrior1YTDDuration8017000000JPY
Cost of salesCurrentYTDDuration8559000000JPY
Gross profitPrior1YTDDuration7252000000JPY
Gross profitCurrentYTDDuration7463000000JPY
Selling general and administrative expensesPrior1YTDDuration5587000000JPY
Selling general and administrative expensesCurrentYTDDuration5759000000JPY
Operating incomePrior1YTDDuration1664000000JPY
Operating incomeCurrentYTDDuration1704000000JPY
Interest income noiPrior1YTDDuration0JPY
Interest income noiCurrentYTDDuration0JPY
Dividends income noiPrior1YTDDuration177000000JPY
Dividends income noiCurrentYTDDuration178000000JPY
Other noiPrior1YTDDuration34000000JPY
Other noiCurrentYTDDuration19000000JPY
Non operating incomePrior1YTDDuration212000000JPY
Non operating incomeCurrentYTDDuration197000000JPY
Interest expenses noePrior1YTDDuration13000000JPY
Interest expenses noeCurrentYTDDuration11000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass